Hemostatic Efficacy of Pathogen-Inactivated Blood Components

Abstract

Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities. Plasma is treated with solvent–detergent to disrupt enveloped viruses, or with photoactive agents methylene blue plus light, or amotosalen (AM) or riboflavin (RF) plus ultraviolet (UV) light, to disrupt pathogen nucleic acids. PI plasmas have average clotting factor activities of 75 to 85% of untreated plasma. PI plasmas are generally equivalent to regular plasma in randomized clinical trials (RCTs) in regard to coagulation test corrections and bleeding outcomes, except for one trial in which RF plasma was inferior for prothrombin time correction. Platelets are treated with UV plus RF or AM. In RCTs, the mean 1-hour corrected count increments from PI platelets are 66 to 94% (trials median, 75%) of those from untreated platelets. PI platelets also have lifespans of 4 to 5 days after 5 days of storage, compared with 6 to 7 days for untreated platelets. Bleeding outcomes comparing PI versus non-PI platelets in RCTs have been equivalent, except one study with more bleeding on AM platelets. Platelet treatment with UVC light alone for PI has entered clinical trials.

Keywords

blood transfusion - blood component transfusion - pathogen inactivation - pathogen reduction technology - plasma - platelet transfusion

• References

• 1 Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutiérrez L. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apheresis Sci 2015; 52 (1) 19-34
• 2 Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014; 9 (1) 30-36
• 3 U.S. Food and Drug Administration. Octaplas. Silver Spring, MD: Consumer Health Information. July 3, 2015. Available at: http://www.fda.gov/forconsumers/consumerupdates/ucm336140.htm . Accessed July 15, 2015
• 4 U.S. Food and Drug Administration. INTERCEPT Blood System for Plasma. Silver Spring, MD: Consumer Affairs Branch, CBER; January 7, 2015. Available at: http://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/premarketapprovalspmas/ucm427204.htm . Accessed July 15, 2015
• 5 U.S. Food and Drug Administration INTERCEPT Blood System for Platelets. Silver Spring, MD: Consumer Affairs Branch, CBER; January 22, 2015. Available at: http://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/premarketapprovalspmas/ucm427488.htm . Accessed July 15, 2015
• 6 Businesswire First INTERCEPT pathogen reduced platelet units produced in the continental US. Business Wire, June 29, 2015. Available at: http://www.businesswire.com/news/home/20150629005348/en
• 7 Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014; 41 (4) 309-325
• 8 Stramer SL, Hollinger FB, Katz LM , et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 (Aug, Suppl 2) 1S-29S
• 9 Heger A, Svae T-E, Neisser-Svae A, Jordan S, Behizad M, Römisch J. Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009; 97 (3) 219-225
• 10 Marks DC, Faddy HM, Johnson L. Pathogen reduction technologies. ISBT Sci Ser 2014; 9: 44-50
• 11 Bhutani VK ; Committee on Fetus and Newborn; American Academy of Pediatrics. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2011; 128 (4) e1046-e1052
• 12 Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2013; 53 (7) 1603-1618
• 13 AABB . Listing of countries in which pathogen reduction technology systems and products are in use. Bethesda, MD: AABB; March 2015. Available at: http://www.aabb.org/tm/eid/Documents/prt-systems-in-use-country-listing.pdf . Accessed July 15, 2015
• 14 Jackman RP, Deng X, Bolgiano D , et al. Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. Transfusion 2014; 54 (3) 672-680
• 15 Jackman RP, Heitman JW, Marschner S, Goodrich RP, Norris PJ. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 2009; 49 (12) 2686-2699
• 16 Ozier Y, Muller J-Y, Mertes P-M , et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion 2011; 51 (10) 2102-2110
• 17 Jilma-Stohlawetz P, Kursten FW, Walasek C , et al. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. Transfusion 2011; 51 (6) 1228-1240
• 18 Tobian AAR, Fuller AK, Uglik K , et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment. Transfusion 2014; 54 (6) 1523-1529 , quiz 1522
• 19 Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 2012; 52 (8) 1673-1686 , quiz 1673
• 20 Picker SM. In-vitro assessment of platelet function. Transfus Apheresis Sci 2011; 44 (3) 305-319
• 21 Lawrie AS, Green L, Canciani MT , et al. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang 2010; 99 (3) 232-238
• 22 Coene J, Devreese K, Sabot B, Feys HB, Vandekerckhove P, Compernolle V. Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion 2014; 54 (5) 1321-1331
• 23 Larrea L, Ortiz-de-Salazar M-I, Martínez P, Roig R. Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies. Transfus Apheresis Sci 2015; 52 (3) 305-310
• 24 Pelletier JPR, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006; 19 (1) 205-242
• 25 Feys HB, Van Aelst B, Devreese K , et al. Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Vox Sang 2014; 106 (4) 307-315
• 26 Inbal A, Epstein O, Blickstein D, Kornbrot N, Brenner B, Martinowitz U. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 1993; 4 (4) 599-604
• 27 Santagostino E, Mancuso ME, Morfini M , et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 2006; 91 (5) 634-639
• 28 de Alarcon P, Benjamin R, Dugdale M , et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45 (8) 1362-1372
• 29 Hambleton J, Wages D, Radu-Radulescu L , et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42 (10) 1302-1307
• 30 Williamson LM, Llewelyn CA, Fisher NC , et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39 (11–12) 1227-1234
• 31 Bindi ML, Miccoli M, Marietta M , et al. Solvent detergent vs. fresh frozen plasma in cirrhotic patients undergoing liver transplant surgery: a prospective randomized control study. Vox Sang 2013; 105 (2) 137-143
• 32 Lerner RG, Nelson J, Sorcia E , et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000; 79 (3) 161-167
• 33 Haubelt H, Blome M, Kiessling AH , et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002; 82 (1) 9-14
• 34 Bartelmaos T, Chabanel A, Léger J , et al. Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013; 53 (6) 1335-1345
• 35 Mintz PD, Bass NM, Petz LD , et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107 (9) 3753-3760
• 36 Stanojkovic Z, Balint B, Antic A, Todorovic M, Ostojic G, Pavlovic M. Clinical efficacy of riboflavin and ultraviolet light inactivated fresh frozen plasma evaluated with INR-quantification. Transfus Apheresis Sci 2012; 47 (1) 33-37
• 37 Keeling DM, Luddington R, Allain J-P, Lawrie AS, Williamson LM. Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. Br J Haematol 1997; 96 (1) 194-197
• 38 Hornsey VS, Young DA, Docherty A, Hughes W, Prowse CV. Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration. Transfus Med 2004; 14 (5) 369-374
• 39 Cardigan R, Philpot K, Cookson P, Luddington R. Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. Transfusion 2009; 49 (4) 696-703
• 40 Ettinger A, Miklauz MM, Bihm DJ, Maldonado-Codina G, Goodrich RP. Preparation of cryoprecipitate from riboflavin and UV light-treated plasma. Transfus Apheresis Sci 2012; 46 (2) 153-158
• 41 Cid J, Caballo C, Pino M , et al. Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light. Transfusion 2013; 53 (3) 600-605
• 42 El-Ekiaby M, Goubran HA, Radosevich M, Abd-Allah A, El-Ekiaby A, Burnouf T. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. Haemophilia 2011; 17 (5) e884-e888
• 43 Kaiser-Guignard J, Canellini G, Lion N, Abonnenc M, Osselaer J-C, Tissot JD. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014; 28 (6) 235-241
• 44 van Rhenen D, Gulliksson H, Cazenave J-P , et al; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101 (6) 2426-2433
• 45 McCullough J, Vesole DH, Benjamin RJ , et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104 (5) 1534-1541
• 46 Snyder E, McCullough J, Slichter SJ , et al; SPRINT Study Group. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45 (12) 1864-1875
• 47 Janetzko K, Cazenave J-P, Klüter H , et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45 (9) 1443-1452
• 48 Kerkhoffs JL, van Putten WLJ, Novotny VMJ , et al; Dutch - Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150 (2) 209-217
• 49 Lozano M, Knutson F, Tardivel R , et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153 (3) 393-401
• 50 Mirasol Clinical Evaluation Study Group.. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50 (11) 2362-2375
• 51 Abonnenc M, Sonego G, Kaiser-Guignard J , et al. In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfus 2015; 13 (2) 255-264
• 52 Van Aelst B, Feys HB, Devloo R, Vanhoorelbeke K, Vandekerckhove P, Compernolle V. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. Vox Sang 2015; 108 (4) 328-339
• 53 Seghatchian J, Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. Transfus Apheresis Sci 2012; 46 (2) 221-229
• 54 Apelseth TO, Bruserud Ø, Wentzel-Larsen T, Bakken AM, Bjørsvik S, Hervig T. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 47 (4) 653-665
• 55 Middelburg RA, Roest M, Ham J, Coccoris M, Zwaginga JJ, van der Meer PF. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion 2013; 53 (8) 1780-1787
• 56 Verhaar R, Dekkers DWC, De Cuyper IM, Ginsberg MH, de Korte D, Verhoeven AJ. UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008; 112 (13) 4935-4939
• 57 Van Aelst B, Devloo R, Vandekerckhove P, Compernolle V, Feys HB. Ultraviolet c light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro. Transfusion 2015; 55 (10) 2404-2414
• 58 Schubert P, Coupland D, Culibrk B, Goodrich RP, Devine DV. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013; 53 (12) 3164-3173
• 59 Johansson PI, Simonsen AC, Brown PN , et al. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion 2013; 53 (9) 2043-2052
• 60 Hechler B, Ohlmann P, Chafey P , et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013; 53 (6) 1187-1200
• 61 Miyaji R, Sakai M, Urano H, Nakata K, Sakamoto H, Shirahata A. Decreased platelet aggregation of platelet concentrate during storage recovers in the body after transfusion. Transfusion 2004; 44 (6) 891-899
• 62 Snyder E, Raife T, Lin L , et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004; 44 (12) 1732-1740
• 63 AuBuchon JP, Herschel L, Roger J , et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45 (8) 1335-1341
• 64 Bashir S, Cookson P, Wiltshire M , et al. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 2013; 53 (5) 990-1000
• 65 US National Institutes of Health . ClinicalTrials.gov. Italian Platelet Technology Assessment Study (IPTAS), identifier NCT01642563. Bethesda, MD: National Institutes of Health, July 16, 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01642563 . Accessed July 17, 2015
• 66 Nederlands Trial Register . The PREPAReS study: pathogen reduction evaluation & predictive analytical rating score, identifier NTR2106. Amsterdam: Nederlands Trial Register, 2013. Available at: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2106 . Accessed July 17, 2015
• 67 Thiele T, Pohler P, Kohlmann T , et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction - a phase I clinical trial. Vox Sang 2015; 109 (1) 44-51